NQ HCIF GP’s Revance Therapeutics, Inc. RVNC Stock Holding History

NQ HCIF GP’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$50.2M	Hold	3,096,650	–	–	100%	1
2016 Q2	$42.1M	Hold	3,096,650	–	–	100%	1
2016 Q1	$54.1M	Hold	3,096,650	–	–	100%	1
2015 Q4	$106M	Hold	3,096,650	–	–	100%	1
2015 Q3	$92.2M	Hold	3,096,650	–	–	100%	1
2015 Q2	$99M	Hold	3,096,650	–	–	100%	1
2015 Q1	$64.2M	Hold	3,096,650	–	–	100%	1
2014 Q4	$52.5M	Buy	+3,096,650	New	+$54.1M	100%	1

Other funds holding RVNC

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

NQ HCIF GP's RVNC Position: Q3 2016 in Review

NQ HCIF GP held its Revance Therapeutics, Inc. (RVNC) position steady in Q3 2016 at 3,096,650 shares worth $50.2M. The position accounts for 100% of the portfolio, ranked #1.

NQ HCIF GP first reported a position in RVNC in Q4 2014 and has held it in 8 quarters since. The position peaked at $106M in Q4 2015. 74 funds tracked by Wall St. Rank hold RVNC as of Q3 2016.

NQ HCIF GP held 3,096,650 shares of Revance Therapeutics, Inc. worth $50.2M as of Q3 2016.
NQ HCIF GP left its Revance Therapeutics, Inc. share count unchanged in Q3 2016.
Revance Therapeutics, Inc. made up 100% of NQ HCIF GP's portfolio in Q3 2016, its #1 holding.
NQ HCIF GP first reported a position in Revance Therapeutics, Inc. in Q4 2014 and has held it in 8 quarters since.
NQ HCIF GP's Revance Therapeutics, Inc. position peaked at $106M in Q4 2015.
74 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2016.

Based on NQ HCIF GP's 13F filing for Q3 2016, filed 27 Oct 2016.